Table 2.

Host-targeted therapeutics for Chagas disease.

Host-targeted Drug	Classification	Mode of action	Reference
Cannabinoids, SQ29548	inhibitors	G protein couple receptor	Scharfstein et al., 2000; Todorov et al., 2003; Croxford et al., 2005;Ashton et al., 2007; Wallukat et al., 2010; Kawano et al., 2011
Carvedilol	β-adrenergic receptor blocker	β-adrenergic receptor	Botoni et al., 2007
SB-431542 compound	inhibitor	TGF-β type I receptor kinase	Silva et al., 1991; Araujo-Jorge et al., 2002; Waghabi et al., 2005; Waghabi et al., 2007
Terpenoides	Inhibitors	NF-κB signaling	Petersen et al., 2006; Ronco et al., 2010; da Silva et al., 2013; Sulsen et al., 2013
Lycopodium clavatum	immunomodulator	Induces Th1 immune responses	Brustolin Aleixo et al., 2017; Lovo-Martins et al., 2017; Otta et al., 2018